Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Oxford Cancer Centre and the Oxford ECMC are launching a new data initiative to maximize the discovery potential of samples and information collected during clinical trials.

Too often translational endpoints in clinical trials are sacrificed when core services are stretched. This is why we have decided to create a new digital initiative: the Oxford Translational Data Platform (TDP) to facilitate secondary data use from clinical trials and enable Oxford researchers to extract maximum value from patient samples, perform multi-level correlative analyses and facilitate exploratory research to seed further translational studies.

Andrew Blake who built and successfully validated the platform for the S:CORT clinical trial said of the platform:


The Oxford Translational Data Platform will serve as a catalyst for collaboration between data scientists, clinicians and wet lab researchers to ensure that maximum value for patients is extracted from high-quality data sets

Scientists who want to access the data on the platform can do it through a bespoke cBioportal page after a short training provided by the TDP team, or download the data for more complex analysis. Data can be used to increase sample numbers, as a control cohort, to generate preliminary data or anything else that would advance our understanding of cancer with the help of real-world trial data.

The TDP welcomes data from open or closed clinical trials and studies: single cell and bulk RNASeq expression data, NGS mutations, SNPs, copy number, methylation, proteomics, IHC scores and images, H&E images, MRI, clinical data, and outputs of machine learning algorithms are combined into a single, secure, user-friendly, multi-omic data platform.  

Over 800 colorectal patients (S:CORT), 250 oesophageal cancer patients (SCOPE) and 40 breast cancer patients (FRONTIER) are already on the platform, and new trials will be added every few months.